Archimed has made its first investment from the MED IV fund in Organika Health Products, a Vancouver-based nutraceutical company founded in 1990. The deal marks Archimed’s seventh nutraceutical investment and was sourced through a team member’s relationship with the founding family. Organika produces supplements for hydration, collagen, protein, immunity, gut health, sleep, and more, and claims to lead the Canadian nutraceutical market.
Aaron Chin will remain CEO, and Archimed will apply its Med Value template to expand the brand into new channels and geographies. No financial terms were disclosed. MED IV closed on €1.5 billion in September, while MED III closed on €650 million in 2021.
Archimed manages $15 billion across its funds.
Source: PE Hub · Summarized by HeadlinesBriefing